Tag Archives: recurrence
Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer
BACKGROUND: Most women with advanced epithelial ovarian cancer will ultimately develop recurrent disease after completion of initial treatment with primary surgery and adjuvant chemotherapy. Secondary cytoreductive surgery may have survival benefits in selected patients. However, a number of chemotherapeutic agents … Continue reading
Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer
First-line chemotherapy fails in more than 20% of patients with epithelial ovarian cancer and about 40—50% of women who respond to initial treatment relapse within 2 years. In the recurrent setting, second-line chemotherapeutic agents have a 15—20% response rate with … Continue reading
Phase II study of liposomal cisplatin (SPI-77) in platinum-sensitive recurrences of ovarian cancer
BACKGROUND: Cisplatin is a highly effective chemotherapeutic agent against epithelial ovarian cancer but is associated with significant toxicities. SPI-77 is a liposomal pegylated formulation of cisplatin that was developed to reduce systemic toxicity and to better deliver cisplatin to tumors. … Continue reading
Why cancer drugs lose their power
For 30 years, the chemotherapy drug cisplatin has been one of doctors’ first lines of defense against tumors, especially those of the lung, ovary and testes. While cisplatin is often effective when first given, it has a major drawback: Tumors … Continue reading
Magee-Womens Hospital of UPMC Launches Clinical Trial for Patients with Recurrent Ovarian Cancer
Magee-Womens Hospital of UPMC will be the only site in Western Pennsylvania for a clinical trial of ABT-888, a drug previously proven in combination treatments to improve chemotherapy’s effectiveness by lowering cancer cells’ resistance to treatment. ABT-888 works by targeting … Continue reading
Tamoxifen for relapse of ovarian cancer
BACKGROUND: Tamoxifen is an important drug for treating breast cancer. Ovarian cancer cells are known to possess receptors for hormones and may thus also respond to tamoxifen. OBJECTIVES: Tamoxifen is used to treat breast cancer in women whose tumours have … Continue reading
Combined positron emission tomography-computed tomography and tumor markers for detecting recurrent ovarian cancer (Arch Gynecol Obstet)
OBJECTIVE: To evaluate the accuracy of integrated FDG-PET/CT and tumor markers for the depiction of recurrent ovarian carcinoma. METHODS: Patients with pathologically proven ovarian cancer, who underwent cytoreductive surgery and 3-6 cycles of adjuvant chemotherapy, were included in this study. … Continue reading
Patient Surveillance After Ovarian Cancer Treatment Is Variable: Presented at SSO
New data indicate that there is marked variability in the intensity of patient surveillance after curative-intent treatment for ovarian cancer. The results were released here on March 6 at the 2010 Society of Surgical Oncology Annual Cancer Symposium (SSO). Garo … Continue reading
Surveillance for the detection of recurrent ovarian cancer: Survival impact or lead-time bias? (Gynecol Oncol)
OBJECTIVE: To compare the survival impact of diagnosing recurrent disease by routine surveillance testing versus clinical symptomatology in patients with recurrent epithelial ovarian cancer (EOC) who have achieved a complete response following primary therapy. METHODS: We identified all patients who … Continue reading
